US EditionTrump, AstraZeneca announce US drug pricing deal at White House
AstraZeneca will offer Medicaid drugs at the lowest prices in developed countries and invest $50 billion in U.S. manufacturing, creating 3,600 jobs, officials said.
- President Donald Trump plans to announce a deal with AstraZeneca to lower drug prices for low-income Americans, according to a White House official.
- The agreement includes a most-favored-nation pricing model aimed at making prescriptions affordable.
- AstraZeneca CEO Pascal Soriot will attend the announcement in the Oval Office, as stated by the official.
- The TrumpRx website for direct-to-consumer sales of discounted drugs will not be live until 2026, according to a senior administration official.
200 Articles
200 Articles
Trump, AstraZeneca announce US drug pricing deal at White House - West Hawaii Today
President Donald Trump unveiled a deal with UK-based drugmaker AstraZeneca on Friday under which the company will sell some medicines at a discount to the government’s Medicaid health plan in exchange for tariff relief, similar to a drug pricing pact reached last week with Pfizer.
Trump Strikes Landmark Deal with AstraZeneca to Lower Drug Prices for Americans
In a dramatic escalation of his “America First” agenda, President Donald Trump announced a sweeping new agreement with pharmaceutical giant AstraZeneca aimed at slashing prescription drug costs for American patients. The deal, revealed Friday, makes AstraZeneca the second major company—after Pfizer—to commit to “most-favored-nation” pricing, meaning the United States will pay no more for drugs than any other developed nation. Speaking from the W…
Donald Trump urges pharmaceutical companies to reduce their prices. Now, a second company has entered into an agreement with AstraZeneca. In return, there should be tariff reductions.
Coverage Details
Bias Distribution
- 63% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
